Daily Medication Pearl: Sacituzumab govitecan-hziy (Trodelvy) for Breast Cancer

Sacituzumab govitecan-hziy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 or more prior systemic therapies, at least 1 of which for metastatic disease.

Medication Pearl of the Day: Sacituzumab govitecan-hziy (Trodelvy)

Indication: Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received 2 or more prior systemic therapies, at least 1 of which for metastatic disease.

Insight:

  • Dosing: The recommended dose is 10 mg/kg once weekly on days 1 and 8 of continuous 21-day treatment cycles until disease progression or unacceptable toxicity.
  • Dosage form: For injection 180 mg lyophilized powder in single-dose vials for reconstitution.
  • Adverse events (AEs): The most common AEs (incidence >25%) are neutropenia, nausea, diarrhea, fatigue, alopecia, anemia, vomiting, constipation, decreased appetite, rash, and abdominal pain.
  • Mechanism of action: Sacituzumab govitecan-hziy is a Trop-2-directed antibody-drug conjugate. The humanized antibody recognizes Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a linker.
  • Manufacturer: Gilead

Sources: